Citations

Clear

959 citation(s) found for "Service, F J".

Prediction of Short- and Long-Term Mortality in Takotsubo Syndrome: The InterTAK Prognostic Score
Wischnewsky, Manfred , Candreva, Alessandro , Bacchi, Beatrice , Cammann, Victoria L. , Kato, Ken , Szawan, Konrad A. , Gili, Sebastiano , Citro, Rodolfo , Bossone, Eduardo , Franke, Jennifer , Sorici‐Barb, Ioana, Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Napp, L. Christian , Budnik, Monika , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , El‐Battrawy, Ibrahim , Akın, İbrahim , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Winchester, David E. , Ukena, Christian , Poglajen, Gregor , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Prasad, Abhiram , Rihal, Charanjit S. , Bianco, Matteo , Jörg, Lucas, Rickli, Hans , Kobayashi, Yoshio, Böhm, Michael , Maier, Lars S. , Pinto, Fausto J. , Widimský, Petr , Borggrefe, Martin, Felix, Stephan B. , Opolski, Grzegorz , Rottbauer, Wolfgang , Pieske, Burkert , Katus, Hugo A. , Horowitz, John D. , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , D’Ascenzo, Fabrizio , Dichtl, Wolfgang , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Rihal, Charanjit S. , Liu, Kan , Schulze, Paul Christian , Nguyen, Thanh Ha Tuan , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T. , Bianco, Matteo

Mayo Clinic

European Journal of Heart Failure | August 27, 2019 | Volume: 21 | Issue: 11 | Pages: 1469-1472

10.1002/ejhf.1561 | PMID 31452320 Get It

Retinoblastoma vascular perfusion and intra‐arterial chemotherapy cycle requirements
Lim, Li‐Anne , Ancona‐Lezama, David , Yu, Michael D. , Lim, Li-Anne S , Dalvin, Lauren A. , Jabbour, Pascal , Shields, Carol L.

Mayo Clinic

Clinical & Experimental Ophthalmology | August 21, 2019 | Volume: 47 | Issue: 9 | Pages: 1164-1172

10.1111/ceo.13616 | PMID 31432625 Get It

AbstractImportanceRetinoblastoma is a life‐ and sight‐threatening malignancy.BackgroundTo assess the relationship between tumour perfusion and intra‐arterial chemotherapy (IAC) requirements to achieve retinoblastoma control.DesignRetrospective case series at the Ocular Oncology Service of Wills Eye Hospital (Philadelphia, Pennsylvania).ParticipantsFifty‐nine eyes of 55 patients.MethodsReview of medical and fluorescein angiography (FA) records for retinoblastoma treated with primary or secondary IAC from 2012 to 2017. Vascular supply of the main tumour was evaluated in the pre‐treatment FA.Main Outcome MeasuresTumour fluorescence was classified as partial <67% or complete tumour perfusion >67%. Partially vs completely perfused tumours were compared for IAC cycle requirements.ResultsThere were 59 eyes of 55 patients with pre‐treatment FA managed with IAC. Partially perfused tumours (n = 20, 34%) required fewer IAC infusions than completely perfused tumours (n = 39, 66%) (2.5 vs 3.7 infusions, P = .02), even after adjustment for confounding factors (tumour diameter, thickness and drug scheme, adjusted P = .04). Tumour perfusion correlated with number of IAC cycles required for tumour control (r = 0.46, P < .001). For primary IAC (n = 18, 31%), tumour perfusion was not associated with number of IAC cycles (P = .63). For secondary IAC (n = 41, 69%), partially perfused tumours (n = 15, 37%) required fewer IAC infusions than completely perfused tumours (n = 26, 63%) (2.1 vs 3.7 infusions, P < .01).Conclusions and RelevanceFA demonstrating partial retinoblastoma tumour perfusion is associated with fewer IAC cycle requirements for secondary but not primary IAC. FA might be useful in judging anticipated treatment cycles of retinoblastoma managed with primary or secondary IAC.
Evaluation After Sudden Death in the Young
Gray, Belinda , Ackerman, Michael J. , Semsarian, Christopher , Behr, Elijah R. , Behr, Elijah Raphael , Gray, Belinda

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 19, 2019 | Volume: 12 | Issue: 8 | Pages: No page available

10.1161/circep.119.007453 | PMID 31422686 Get It

Sudden cardiac death is defined as a death occurring usually within an hour of onset of symptoms, arising from an underlying cardiac disease. Sudden cardiac death is a complication of a number of cardiovascular diseases and is often unexpected. In individuals aged <35 years, unexplained sudden cardiac death is the most common presentation. A significant proportion of sudden cardiac death in the young (≤35 years) events may be precipitated by underlying inherited cardiac conditions, including both heritable cardiomyopathies and inherited arrhythmia syndromes (also known as cardiac channelopathies). Tragically, sudden death may be the first manifestation of the disease in a family and, therefore, clinical and genetic evaluation of surviving family members forms a key role in diagnosing the underlying inherited cardiac condition in the family. This is particularly relevant when considering that most inherited cardiac conditions are inherited in an autosomal dominant manner meaning that surviving family members have a 50% chance of inheriting the same disease substrate. This review will outline the underlying causes of sudden cardiac death in the young and outline our universal approach to familial evaluation following a young person’s sudden death.
Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy
Neumann, Hartmut P.H., Tsoy, Uliana, Amodru, Vincent , Walz, Martin K. , Kaur, Ravinder Jeet , McKenzie, Travis J. , Qi, Xiao-Ping , Bandgar, Tushar , Petrov, Roman , Yukina, M. Yu. , Roslyakova, Anna , Horst‐Schrivers, Anouk N.A. van der , Berends, Annika M.A. , Hoff, Ana O. , Castroneves, Luciana Audi , Rizzati, Silvia, Mian, Caterina , Dvořáková, Šárka , Hasse-Lazar, Kornelia , Kvachenyuk, Andrey, Pęczkowska, Mariola , Loli, Paola , Erenler, Feyza , Krauß, Tobias , Almeida, Madson Q. , Liu, Longfei , Zhu, Feizhou , Recasens, Mònica, Wohllk, Nelson , Corssmit, Eleonora P.M. , Kunavisarut, Tada , Schalin‐Jäntti, Camilla , Castinetti, Frédéric , Vlček, Petr , Beltsevich, D. G. , Егоров, В. И. , Schiavi, Francesca , Links, Thera P. , Lechan, Ronald M. , Bausch, Birke, Group, for the International Bilateral-Pheochromocytoma-Registry, Ngeow, Joanne , Jarząb, Barbara , Hudiakova, N. V. , Fragoso, Maria Candida Barisson Villares , Grineva, Elena , Tsoy, U. A. , Opocher, Giuseppe , Ngeow, Joanne , Bancos, Irina , Tirosh, Amit , Ferrara, Alfonso Massimiliano , Recasens, Monica, Shafigullina, Zulfiya R. , Calissendorff, Jan , Grozinsky‐Glasberg, Simona , Egorov, Viacheslav I., Young, William F. , Eng, Charis , Almeida, Madson Q

Mayo Clinic

JAMA Network Open | August 9, 2019 | Volume: 2 | Issue: 8 | Pages: e198898

10.1001/jamanetworkopen.2019.8898 | PMID 31397861 Get It

Lipid droplet size directs lipolysis and lipophagy catabolism in hepatocytes
Schott, Micah B. , Weller, Shaun G. , Schulze, Ryan J. , Krueger, Eugene W. , Drizyte‐Miller, Kristina , Casey, Carol A. , McNiven, Mark A. , Casey, Carol A , Schott, Micah B , Drizyte-Miller, Kristina

Mayo Clinic

Journal of Cell Biology | August 7, 2019 | Volume: 218 | Issue: 10 | Pages: 3320-3335

10.1083/jcb.201803153 | PMID 31391210 Get It

Lipid droplet (LD) catabolism in hepatocytes is mediated by a combination of lipolysis and a selective autophagic mechanism called lipophagy, but the relative contributions of these seemingly distinct pathways remain unclear. We find that inhibition of lipolysis, lipophagy, or both resulted in similar overall LD content but dramatic differences in LD morphology. Inhibition of the lipolysis enzyme adipose triglyceride lipase (ATGL) resulted in large cytoplasmic LDs, whereas lysosomal inhibition caused the accumulation of numerous small LDs within the cytoplasm and degradative acidic vesicles. Combined inhibition of ATGL and LAL resulted in large LDs, suggesting that lipolysis targets these LDs upstream of lipophagy. Consistent with this, ATGL was enriched in larger-sized LDs, whereas lipophagic vesicles were restricted to small LDs as revealed by immunofluorescence, electron microscopy, and Western blot of size-separated LDs. These findings provide new evidence indicating a synergistic relationship whereby lipolysis targets larger-sized LDs to produce both size-reduced and nascently synthesized small LDs that are amenable for lipophagic internalization.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Tam, Constantine S. , Opat, Stephen , Burger, Jan A. , Cull, Gavin , Gottlieb, David , Johnston, Patrick B. , Marlton, Paula , Seymour, John F. , Simpson, David , Tedeschi, Alessandra , Elstrom, Rebecca, Yu, Yiling , Tang, Zhiyu , Han, Lynn , Huang, Jane , Novotny, William , Wang, Lai, Roberts, Andrew W. , Trotman, Judith , Burger, Jan A , Seymour, John F , Simpson, David , Roberts, Andrew W , Tam, Constantine S , Opat, Stephen , Harrup, Rosemary Anne , Muñoz, Javier

Mayo Clinic

Blood | July 24, 2019 | Volume: 134 | Issue: 11 | Pages: 851-859

10.1182/blood.2019001160 | PMID 31340982 Get It

Abstract Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily or 160 mg twice daily. Part 2 (expansion) consisted of disease-specific cohorts, including treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The primary end points were safety and tolerability, and definition of the maximum tolerated dose (part 1). Additional end points included pharmacokinetics/pharmacodynamics and preliminary efficacy. Reported herein are results from 144 patients enrolled in the dose-finding and CLL/SLL cohorts. No dose-limiting toxicities occurred in dose escalation. Median BTK occupancy in peripheral blood mononuclear cells was &gt;95% at all doses. Sustained complete (&gt;95%) BTK occupancy in lymph node biopsy specimens was more frequent with 160 mg twice daily than 320 mg once daily (89% vs 50%; P = .0342). Consequently, 160 mg twice daily was selected for further investigation. With median follow-up of 13.7 months (range, 0.4-30.5 months), 89 CLL/SLL patients (94.7%) remain on study. Most toxicities were grade 1/2; neutropenia was the only grade 3/4 toxicity observed in &gt;2 patients. One patient experienced a grade 3 subcutaneous hemorrhage. Among 78 efficacy-evaluable CLL/SLL patients, the overall response rate was 96.2% (95% confidence interval, 89.2-99.2). Estimated progression-free survival at 12 months was 100%. Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site
Mellor, Greg , Panwar, Pankaj, Lee, Andrea K, Hathaway, Julie , Bartels, Kirsten , Balaji, Seshadri , Roberts, Jason D. , Simpson, Chris S., Boczek, Nicole J. , Tester, David J. , Radbill, Andrew E. , Mok, Ngai‐Shing, Hamilton, Robert M. , Kaufman, Elizabeth S. , Eugenio, Paul, January, Craig T., McDaniel, George, Leather, Richard, Falik, Shelley, Behr, Elijah R. , Wilde, Arthur A.M. , Sanatani, Shubhayan , Ackerman, Michael J. , Petegem, Filip Van , Laksman, Zachary , Behr, Elijah Raphael , Sanatani, Shubhayan , Hamilton, Robert , Steinberg, Christian , Christian, Susan , Weiss, Raul , Erickson, Christopher, Krahn, Andrew D.

Mayo Clinic

EP Europace | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1725-1732

10.1093/europace/euz215 | PMID 31408100 Get It

Abstract Aims Pathogenic gain-of-function variants in CACAN1C cause type-8 long QT syndrome (LQT8). We sought to describe the electrocardiographic features in LQT8 and utilize molecular modelling to gain mechanistic insights into its genetic culprits. Methods and results Rare variants in CACNA1C were identified from genetic testing laboratories. Treating physicians provided clinical information. Variant pathogenicity was independently assessed according to recent guidelines. Pathogenic (P) and likely pathogenic (LP) variants were mapped onto a 3D modelled structure of the Cav1.2 protein. Nine P/LP variants, identified in 23 patients from 19 families with non-syndromic LQTS were identified. Six variants, found in 79% of families, clustered to a 4-residue section in the cytosolic II–III loop region which forms a region capable of binding STAC SH3 domains. Therefore, variants may affect binding of SH3-domain containing proteins. Arrhythmic events occurred in similar proportions of patients with II–III loop variants and with other P/LP variants (53% vs. 48%, P = 0.41) despite shorter QTc intervals (477 ± 31 ms vs. 515 ± 37 ms, P = 0.03). A history of sudden death was reported only in families with II–III loop variants (60% vs. 0%, P = 0.03). The predominant T-wave morphology was a late peaking T wave with a steep descending limb. Exercise testing demonstrated QTc prolongation on standing and at 4 min recovery after exercise. Conclusion The majority of P/LP variants in patients with CACNA1C-mediated LQT8 cluster in an SH3-binding domain of the cytosolic II–III loop. This represents a ‘mutation hotspot’ in LQT8. A late-peaking T wave with a steep descending limb and QT prolongation on exercise are commonly seen.
Factors Associated with Cigarette Use During Airmen’s First Year of Service in the United States Air Force
Little, Melissa A. , Ebbert, Jon O. , Krukowski, Rebecca A. , Halbert, Jennifer P. , Kalpinski, Maj Ryan, Talcott, G. Wayne , Klesges, Robert C. , Patten, Christi A.

Mayo Clinic

Military Medicine | July 9, 2019 | Volume: 185 | Issue: 1-2 | Pages: e212-e220

10.1093/milmed/usz155 | PMID 31287888 Get It

Abstract Introduction Despite declines of cigarette use in the civilian population, military personnel report alarmingly high rates of cigarette use. Enlisted Air Force recruits are required to remain tobacco-free for the first 12 weeks of training, and the majority express confidence they will not use tobacco after the ban; however, most previous smokers return to smoking and many nonsmokers initiate. Understanding the factors associated with cigarette-smoking initiation among non-users and re-initiation among former users is critical for the development of successful tobacco control efforts. Materials and Methods The current study examines predictors of cigarette smoking among a sample of 2,188 USAF personnel after their first year of service. Logistic regression analyses examined associations between baseline predictors and initiation and re-initiation of cigarette smoking at a one-year follow-up. Results Compared to never smokers at both time points, the strongest predictor of smoking initiation over the past 12 months was having owned cigarette-branded merchandise (OR 3.81, 95% CI 1.67, 8.71). Compared to former smokers who remained abstinent, the strongest predictor of re-initiation was intention to use tobacco (OR 2.08, 95% CI 1.53, 2.83). Compared to individuals who initiate, the strongest predictors of re-initiation were prior use of other tobacco products and tobacco use intentions (ORs range 1.85 to 4.63). Conclusions Multiple risk factors are associated with tobacco use. Given that Airmen are tobacco-free for the first 12 weeks of training, tobacco interventions during this period might be more effective. Our findings can be used to tailor interventions to prevent tobacco use in the U.S. military.
Prevalence of Atrial Fibrillation in Patients with Retinal Vessel Occlusion and Its Association: A Systematic Review and Meta-Analysis
Kewcharoen, Jakrin , Tom, Elysse S. , Wiboonchutikula, Chonlanan, Trongtorsak, Angkawipa , Wittayalikit, Chutikarn, Vutthikraivit, Wasawat , Prasitlumkum, Narut , Rattanawong, Pattara , Rattanawong, Pattara , Kewcharoen, Jakrin , Prasitlumkum, Narut

Mayo Clinic

Current Eye Research | July 8, 2019 | Volume: 44 | Issue: 12 | Pages: 1337-1344

10.1080/02713683.2019.1641826 | PMID 31283356 Get It

Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms
Lim, Megan S. , Bailey, Nathanael G. , King, Rebecca L. , Piris, Miguel Á. , Piris, Miguel , Lim, Megan S

Mayo Clinic

American Journal of Clinical Pathology | July 6, 2019 | Volume: 152 | Issue: 3 | Pages: 277-301

10.1093/ajcp/aqz078 | PMID 31278738 Get It

AbstractObjectivesThe 2017 Workshop of the Society for Hematopathology/European Association for Haematopathology reviewed the role of molecular genetics in the diagnosis and biology of lymphoid neoplasms.MethodsThe Workshop Panel reviewed 82 cases.ResultsMolecular genetic testing reveals alterations that expand the spectrum of diseases such as DUSP22 rearrangement in ALK-negative anaplastic large cell lymphoma, large B-cell lymphoma with IRF4 rearrangement, MYD88 mutations in B-cell lymphomas, Burkitt-like lymphoma with 11q aberrations, and diagnostic criteria for high-grade B-cell lymphomas. Therapeutic agents and natural tumor progression may be associated with transcriptional reprogramming that lead to transdifferentiation and lineage switch.ConclusionsApplication of emerging technical advances has revealed the complexity of genetic events in lymphomagenesis, progression, and acquired resistance to therapies. They also contribute to enhanced understanding of the biology of indolent vs aggressive behavior, clonal evolution, tumor progression, and transcriptional reprogramming associated with transdifferentiation events that may occur subsequent to therapy.